Melissa M. Brown

TL;DR: 11-year and 2-year, healthcare sector (ophthalmic) and societal cost perspective reference case, cost-utility analyses comparing bevacizumab, ranibizumAB and aflibercept monotherapies for neovascular age-related macular degeneration (NVAMD) revealed early treatment was 138%-149% more cost-effective than late treatment.

TL;DR: Cataract surgery in both the first eye and second eye, when analyzed by standard health economic methodologies, is highly cost-effective.

TL;DR: Intravitreal NVAMD bevacIZumab, ranibizumab and aflibercept monotherapies accrue considerable financial, returns-on-investment to patients and insurers as they increase national wealth.

TL;DR: Ranibizumab therapy for neovascular AMD in 2015, considering treatment of both eyes, conferred greater patient value gain and improved cost-effectiveness than in 2006, as well as a large monetary return-on-investment to the Gross Domestic Product and nation’s wealth.

TL;DR: In this paper, a comparative effectiveness and cost-utility analysis for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain was performed.